How Oxandrolone (Anavar) Affects ALT

Oxandrolone (Anavar) is a 17-alpha-alkylated oral steroid derived from dihydrotestosterone (DHT), but with a unique structural modification that moderates its hepatotoxic profile:

1. C17-aa structure: Oxandrolone is 17-alpha-alkylated like other oral steroids, giving it oral bioavailability but also hepatotoxic potential.
2. Lower dosing: Effective doses of oxandrolone (20-60 mg/day) are lower than many other oral steroids in absolute milligram terms, reducing total hepatic exposure.
3. Renal excretion: Uniquely among oral steroids, a significant portion of oxandrolone is excreted unchanged by the kidneys rather than being entirely metabolised by the liver. This reduces the hepatic metabolic burden.
4. Reduced cholestatic impact: While oxandrolone can cause cholestasis, the severity is typically less than with oxymetholone or superdrol, likely due to the lower doses and partial renal clearance.
5. Therapeutic precedent: Oxandrolone is one of the few oral steroids with extensive clinical use data. It is prescribed for burn patients, HIV wasting, Turner syndrome, and constitutional growth delay, providing a larger safety database than most anabolic steroids.

Despite being the "mildest" oral steroid for the liver, oxandrolone is still hepatotoxic. It should not be treated as liver-safe.

Low doses (10-20 mg/day):

• ALT may rise only 1-2x ULN (40-80 U/L)
• Many users see minimal liver enzyme changes at this dose
• More commonly used in therapeutic and female contexts

Standard bodybuilding doses (40-60 mg/day):

• ALT typically rises 1.5-3x ULN (60-120 U/L)
• AST rises proportionally
• GGT and bilirubin usually remain within normal limits
• Cholestatic features are uncommon at this dose range

Higher doses (80-100 mg/day):

• ALT can reach 2-4x ULN (80-160+ U/L)
• At these doses, oxandrolone's hepatotoxic profile approaches that of Dianabol
• These doses are uncommon and offer diminishing returns relative to the increased toxicity

Timeline: ALT elevation is generally mild and peaks at weeks 4-6. The slow, modest rise reflects oxandrolone's lower hepatotoxic potency. Recovery is typically rapid after discontinuation.

Pre-cycle: Baseline liver panel. While oxandrolone is relatively mild, pre-existing liver conditions increase risk.

On cycle: Check liver enzymes at week 4-6. For standard doses, more frequent monitoring is usually unnecessary unless symptoms develop.

Post-cycle: Recheck at 4 weeks post-discontinuation (though many users will have normalised by then).

Relaxed but not absent monitoring: Anavar's milder hepatotoxic profile does not mean monitoring can be skipped entirely. Individual variation exists, and occasional users will show disproportionate ALT elevations.

Lipid monitoring: Like all oral steroids, oxandrolone suppresses HDL. While the effect is milder than with stanozolol or other orals, lipid panels should be included in monitoring.

Liver support:

• TUDCA 250-500 mg/day is generally sufficient for Anavar
• NAC 600 mg/day for antioxidant support
• Some users opt to skip TUDCA at very low Anavar doses (20 mg or below), relying on NAC alone

Cycle design:

• Oxandrolone cycles can safely run 6-8 weeks at standard doses
• Some users extend to 10-12 weeks at lower doses (20-30 mg/day), though this is not universally recommended
• Do not stack with other C17-aa oral steroids
• Anavar is commonly used as a "finisher" in the last 6-8 weeks of a longer injectable cycle

Dose optimisation:

• 40-60 mg/day is the effective range for most male bodybuilders
• Above 60 mg/day, the additional benefit is marginal while hepatotoxicity increases
• Women typically use 5-20 mg/day with even lower hepatic impact

Post-cycle: Liver enzymes typically normalise within 2-4 weeks of discontinuation. No special recovery protocol is usually needed beyond standard liver support continuation for 2 weeks.